357 related articles for article (PubMed ID: 25556084)
21. [New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
Páramo JA
Med Clin (Barc); 2013 Oct; 141(8):346-8. PubMed ID: 23831406
[No Abstract] [Full Text] [Related]
22. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
23. Response.
Douketis J; Eikelboom J; Liew A; Bell AD
Can Fam Physician; 2015 Jan; 61(1):24-5. PubMed ID: 25609517
[No Abstract] [Full Text] [Related]
24. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Oberhofer E
MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
[No Abstract] [Full Text] [Related]
25. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
[TBL] [Abstract][Full Text] [Related]
26. New oral therapies for the prevention and treatment of venous thromboembolism.
Hellwig T; Gulseth M
Am J Health Syst Pharm; 2013 Jan; 70(2):113-25. PubMed ID: 23292264
[TBL] [Abstract][Full Text] [Related]
27. Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Turagam MK; Velagapudi P; Bongu NR; Kocheril AG
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):79-86. PubMed ID: 25088126
[TBL] [Abstract][Full Text] [Related]
28. Well-managed warfarin is superior to NOACs.
Trusler M
Can Fam Physician; 2015 Jan; 61(1):23-4. PubMed ID: 25609516
[No Abstract] [Full Text] [Related]
29. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Friedman RJ
Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
[TBL] [Abstract][Full Text] [Related]
30. [New approaches in the treatment of deep vein thrombosis].
Nieto Rodríguez JA
Med Clin (Barc); 2012 Oct; 139 Suppl 2():19-23. PubMed ID: 23498068
[TBL] [Abstract][Full Text] [Related]
31. Switching between oral anticoagulants.
Strasser KM; Qasem A; Madhusudhana S
Hosp Pract (1995); 2014 Aug; 42(3):68-74. PubMed ID: 25255408
[TBL] [Abstract][Full Text] [Related]
32. Oral anticoagulants for stroke prevention in atrial fibrillation.
Senoo K; Lane DA; Lip GY
Curr Probl Cardiol; 2014 Sep; 39(9):319-44. PubMed ID: 25194766
[TBL] [Abstract][Full Text] [Related]
33. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Ezekowitz MD; Kent AP
Circulation; 2014 Oct; 130(17):1505-14. PubMed ID: 25332278
[No Abstract] [Full Text] [Related]
34. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
35. [New anticoagulants in the prevention and treatment of venous thromboembolism].
Keltai M; Keltai K
Orv Hetil; 2011 Jun; 152(25):983-92. PubMed ID: 21642050
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
37. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
38. Oral direct inhibitors of coagulation.
Watson HG
J R Coll Physicians Edinb; 2014; 44(1):46-9. PubMed ID: 24995448
[TBL] [Abstract][Full Text] [Related]
39. [New anticoagulants: better knowledge, better prescriptions].
Boehlen F; de Moerloose P
Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
[TBL] [Abstract][Full Text] [Related]
40. Overview of the new oral anticoagulants: opportunities and challenges.
Yeh CH; Hogg K; Weitz JI
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
